Bayer buys Icon Genetics
Bayer Innovation, a subsidiary of the Bayer Group engaged in developing new fields of business, has acquired Icon Genetics, a biotech company headquartered in Munich, Germany.
Bayer Innovation, a subsidiary of the Bayer Group engaged in developing new fields of business, has acquired Icon Genetics, a biotech company headquartered in Munich, Germany.
Icon Genetics discovers innovative methods for the development and use of engineered plants. In particular, it employs the natural protein production processes in plants as a way of producing therapeutically active substances.
The acquisition will strengthen Bayer's activities aimed at producing specific pharmaceutical substances in plants (plant-made pharmaceuticals, or PMPs). The two companies are already cooperating on research.
No financial details of the acquisition were disclosed.